Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Medical ImagingNuclear Medical

PUBLISHER: Grand View Research | PRODUCT CODE: 1842095

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1842095

Middle East Nuclear Medicine Market Size, Share & Trends Analysis Report By Product (Diagnostics, Therapeutics), By Application (Cardiology, Neurology, Oncology), By End-use (Hospitals, Diagnostic Centers), By Country, And Segment Forecasts, 2025 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4950
Printable PDF & Excel (5-User License)
USD 5950
Printable PDF & Excel (Enterprise License)
USD 7950

Add to Cart

Description

Table of Contents

List of Tables

Middle East Nuclear Medicine Market Summary

The Middle East nuclear medicine market size was estimated at USD 316.50 million in 2024 and is projected to reach USD 727.3 million by 2033, growing at a CAGR of 8.62% from 2025 to 2033. The market is driven by increasing healthcare infrastructure investments and the rising demand for advanced diagnostic and therapeutic options.

The industry is witnessing significant growth due to advancements in both diagnostic and therapeutic applications, coupled with strategic government investments in healthcare infrastructure. Nuclear medicine plays a vital role in the region's healthcare transformation, especially as governments recognize its potential for early disease detection and precision-based treatment. , for example, the UAE is investing heavily in nuclear medicine technologies as part of its Vision 2030 initiative. According to the UAE Ministry of Health and Prevention's Statistical Annual Report of 2023, the government's health policy includes expanding nuclear medicine centers and providing state-of-the-art cancer treatment services across the nation. The report also highlights that there is an ongoing emphasis on enhancing diagnostic capabilities with cutting-edge technologies, including PET and SPECT scanners.

A significant driver of this market growth is the increasing prevalence of chronic diseases, particularly cancer and cardiovascular conditions, which are putting pressure on healthcare systems to adopt advanced diagnostic and treatment modalities. A Gulf News article published on August 9, 2024, reported that Saudi Arabia has approximately 22,000 new cancer cases, with Riyadh leading the kingdom in cancer cases. Of these, about 17,941 are Saudi nationals, and 4,215 are non-Saudis. Breast cancer is the most prevalent type, with about 3,500 cases recorded. Other common cancers include colon cancer (2,200 cases), lymphoma (1,400 cases), and thyroid cancer (600 cases). This alarming increase in cancer cases has created a pressing need for more specialized healthcare services, including nuclear medicine for early diagnosis and effective treatment. Techniques such as PET and SPECT are becoming integral to oncology protocols, helping doctors detect and assess cancers at early stages. With this rising demand, Saudi Arabia has begun integrating advanced nuclear medicine technologies in several hospitals, including the King Faisal Specialist Hospital in Riyadh, which has recently upgraded its nuclear imaging services to handle the increasing patient load. For instance, The fifth annual UAE International Nuclear Medicine Conference, held in April 2025, highlighted the country's advancements in nuclear medicine. Experts reported successful treatments of prostate and endocrine tumors using targeted radiotherapy, with a 100% tumor control rate in 15 cases. The conference also noted that the UAE operates 14 specialized nuclear medicine centers across various emirates, supported by the latest devices and technologies, positioning the country as a regional leader in this specialty.

In addition to diagnostic advances, nuclear medicine's therapeutic applications are expanding rapidly across the region. One notable development is the collaboration between the International Atomic Energy Agency (IAEA) and the UAE, which aims to boost the production of radiopharmaceuticals locally. This collaboration, as outlined in a 2024 IAEA report, is focused on improving the UAE's capacity to produce radiopharmaceuticals for cancer treatment, which will reduce the country's reliance on imports, also make critical therapies more accessible to underserved populations. This initiative is part of a broader regional strategy to develop self-sufficiency in radiopharmaceuticals, thus lowering costs and ensuring more consistent availability of treatment.

Furthermore, Jordan has positioned itself as a leader in nuclear research with its Jordan Research and Training Reactor (JRTR), which has been operational since 2016. This reactor plays a crucial role in producing medical isotopes used in diagnostic and therapeutic nuclear medicine. The JRTR not only strengthens Jordan's domestic capabilities but also positions the country as a key player in the regional nuclear medicine landscape, exporting isotopes to other Middle Eastern countries. This development underscores the growing importance of nuclear medicine in the region and the ongoing efforts to enhance access to advanced healthcare solutions.

Middle East Nuclear Medicine Market Report Segmentation

This report forecasts revenue growth at the regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Middle East nuclear medicine market report based on product, application, end use, and country:

  • Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Diagnostics
    • SPECT
    • TC-99m
    • TL-201
    • GA-67
    • I-123
    • Others
    • PET
    • F-18
    • SR-82/RB-82
    • PYLARIFY (piflufolastat F 18)
    • Illuccix (gallium Ga 68 gozetotide)
    • Others
  • Therapeutics
    • Alpha Emitters
    • RA-223
    • Others
    • Beta Emitters
    • I-131
    • Y-90
    • SM-153
    • Re-186
    • Lu-177
    • Others
    • Brachytherapy
    • Cesium-131
    • Iodine-125
    • Palladium-103
    • Iridium-192
    • Others
  • Application Outlook (Revenue, USD Billion, 2021 - 2033)
  • Cardiology
    • SPECT
    • PET
    • Therapeutic Applications
  • Neurology
  • Oncology
  • Thyroid
    • SPECT
    • Therapeutic Applications
  • Lymphoma
  • Bone Metastasis
    • SPECT
    • Therapeutic Applications
  • Endocrine Tumor
  • Pulmonary Scans
  • Urology
  • Other
  • End Use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospitals
  • Diagnostic Centers
  • Others
  • Country Outlook (Revenue, USD Million, 2021 - 2033)
  • Middle East
    • UAE
    • Saudi Arabia
    • Kuwait
    • Qatar
    • Oman
    • Rest of Middle East
Show more
Product Code: GVR-4-68040-720-6

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and Application Outlook
    • 2.2.2. End Use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Middle East Nuclear Medicine Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Nuclear Medicine Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Pricing Analysis
  • 3.5. Pipeline Analysis
  • 3.6. Patent Expiry Analysis

Chapter 4. Middle East Nuclear Medicine Market: By Product Estimates & Trend Analysis

  • 4.1. Nuclear Medicine Market: Product Segment Dashboard
  • 4.2. Nuclear Medicine Market: Product Movement Analysis, 2024 & 2033 (USD Million)
  • 4.3. Diagnostics
    • 4.3.1. Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.2. SPECT
      • 4.3.2.1. SPECT Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.2.2. TC-99m
        • 4.3.2.2.1. TC-99m Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.2.3. TL-201
        • 4.3.2.3.1. TL-201 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.2.4. GA-67
        • 4.3.2.4.1. GA-67 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.2.5. I-123
        • 4.3.2.5.1. I-123 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.2.6. Others
        • 4.3.2.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.3.3. PET
      • 4.3.3.1. PET Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.2. F-18
        • 4.3.3.2.1. F-18 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.3. SR-82/RB-82
        • 4.3.3.3.1. SR-82/RB-82 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.4. PYLARIFY (piflufolastat F 18)
        • 4.3.3.4.1. PYLARIFY (piflufolastat F 18) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.5. Illuccix (gallium Ga 68 gozetotide)
        • 4.3.3.5.1. Illuccix (gallium Ga 68 gozetotide) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.3.3.6. Others
        • 4.3.3.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Therapeutics
    • 4.4.1. Therapeutics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Alpha Emitters
      • 4.4.2.1. Alpha Emitters Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.2. RA-223
        • 4.4.2.2.1. RA-223 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.2.3. Others
        • 4.4.2.3.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Beta Emitters
      • 4.4.3.1. Beta Emitters Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.2. I-131
        • 4.4.3.2.1. I-131 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.3. Y-90
        • 4.4.3.3.1. Y-90 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.4. SM-153
        • 4.4.3.4.1. SM-153 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.5. Re-186
        • 4.4.3.5.1. Re-186 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.6. Lu-177
        • 4.4.3.6.1. Lu-177 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.3.7. Others
        • 4.4.3.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Brachytherapy
      • 4.4.4.1. Brachytherapy Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.4.2. Cesium-131
        • 4.4.4.2.1. Cesium-131 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.4.3. Iodine-125
        • 4.4.4.3.1. Iodine-125 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.4.4. Palladium-103
        • 4.4.4.4.1. Palladium-103 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.4.5. Iridium-192
        • 4.4.4.5.1. Iridium-192 Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 4.4.4.6. Others
        • 4.4.4.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Middle East Nuclear Medicine Market: Application Estimates & Trend Analysis

  • 5.1. Nuclear Medicine Market: Application Segment Dashboard
  • 5.2. Nuclear Medicine Market: Application Movement Analysis, 2024 & 2033 (USD Million)
  • 5.3. Cardiology
    • 5.3.1. Cardiology Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.2. SPECT
      • 5.3.2.1. SPECT Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.3. PET
      • 5.3.3.1. PET Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.3.4. Therapeutic Applications
      • 5.3.4.1. Therapeutic Applications Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Neurology
    • 5.4.1. Neurology Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Oncology
    • 5.5.1. Oncology Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Thyroid
    • 5.6.1. Thyroid Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.6.2. PET
      • 5.6.2.1. PET Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.6.3. Therapeutic Applications
      • 5.6.3.1. Therapeutic Applications Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Lymphoma
    • 5.7.1. Lymphoma Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Bone Metastasis
    • 5.8.1. Bone Metastasis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.8.2. PET
      • 5.8.2.1. PET Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 5.8.3. Therapeutic Applications
      • 5.8.3.1. Therapeutic Applications Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.9. Endocrine Tumor
    • 5.9.1. Endocrine Tumor Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.10. Pulmonary Scans
    • 5.10.1. Pulmonary Scans Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.11. Urology
    • 5.11.1. Urology Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.12. Other
    • 5.12.1. Other Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Middle East Nuclear Medicine Market: End Use Estimates & Trend Analysis

  • 6.1. Nuclear Medicine Market: End Use Segment Dashboard
  • 6.2. Nuclear Medicine Market: End Use Movement Analysis, 2024 & 2033 (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Diagnostic Centers
    • 6.4.1. Diagnostic Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Others
    • 6.5.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Middle East Nuclear Medicine Market: Regional Estimates & Trend Analysis By Product, Application, End Use

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.3. Middle East
    • 7.3.1. Saudi Arabia
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.2. UAE
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.3. Kuwait
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.4. Qatar
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Regulatory framework/ reimbursement structure
      • 7.3.4.3. Competitive scenario
      • 7.3.4.4. Qatar market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.5. Oman
      • 7.3.5.1. Key country dynamics
      • 7.3.5.2. Regulatory framework/ reimbursement structure
      • 7.3.5.3. Competitive scenario
      • 7.3.5.4. Oman market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.6. Rest of Middle East
      • 7.3.6.1. Key country dynamics
      • 7.3.6.2. Regulatory framework/ reimbursement structure
      • 7.3.6.3. Competitive scenario
      • 7.3.6.4. Rest of Middle East market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Participant Overview
  • 8.3. Financial Overview
  • 8.4. Product Benchmarking
  • 8.5. Company Market Share Analysis, 2024
  • 8.6. Strategy Mapping
  • 8.7. Company Profiles
    • 8.7.1. GE Healthcare
      • 8.7.1.1. Company overview
      • 8.7.1.2. Financial performance
      • 8.7.1.3. Product benchmarking
      • 8.7.1.4. Strategic initiatives
    • 8.7.2. Jubilant Life Sciences Ltd
      • 8.7.2.1. Company overview
      • 8.7.2.2. Financial performance
      • 8.7.2.3. Product benchmarking
      • 8.7.2.4. Strategic initiatives
    • 8.7.3. Nordion (Canada), Inc.
      • 8.7.3.1. Company overview
      • 8.7.3.2. Financial performance
      • 8.7.3.3. Product benchmarking
      • 8.7.3.4. Strategic initiatives
    • 8.7.4. Bracco Imaging S.P.A
      • 8.7.4.1. Company overview
      • 8.7.4.2. Financial performance
      • 8.7.4.3. Product benchmarking
      • 8.7.4.4. Strategic initiatives
    • 8.7.5. The institute for radioelements (IRE)
      • 8.7.5.1. Company overview
      • 8.7.5.2. Financial performance
      • 8.7.5.3. Product benchmarking
      • 8.7.5.4. Strategic initiatives
    • 8.7.6. NTP Radioisotopes SOC Ltd.
      • 8.7.6.1. Company overview
      • 8.7.6.2. Financial performance
      • 8.7.6.3. Product benchmarking
      • 8.7.6.4. Strategic initiatives
    • 8.7.7. The Australian Nuclear Science and Technology Organization
      • 8.7.7.1. Company overview
      • 8.7.7.2. Financial performance
      • 8.7.7.3. Product benchmarking
      • 8.7.7.4. Strategic initiatives
    • 8.7.8. EczacIbasI-Monrol
      • 8.7.8.1. Company overview
      • 8.7.8.2. Financial performance
      • 8.7.8.3. Product benchmarking
      • 8.7.8.4. Strategic initiatives
    • 8.7.9. Lantheus Medical Imaging, Inc
      • 8.7.9.1. Company overview
      • 8.7.9.2. Financial performance
      • 8.7.9.3. Product benchmarking
      • 8.7.9.4. Strategic initiatives
    • 8.7.10. Eckert & Ziegler
      • 8.7.10.1. Company overview
      • 8.7.10.2. Financial performance
      • 8.7.10.3. Product benchmarking
      • 8.7.10.4. Strategic initiatives
    • 8.7.11. Mallinckrodt
      • 8.7.11.1. Company overview
      • 8.7.11.2. Financial performance
      • 8.7.11.3. Product benchmarking
      • 8.7.11.4. Strategic initiatives
    • 8.7.12. Cardinal Health
      • 8.7.12.1. Company overview
      • 8.7.12.2. Financial performance
      • 8.7.12.3. Product benchmarking
      • 8.7.12.4. Strategic initiatives
Show more
Product Code: GVR-4-68040-720-6

List of Tables

  • Table 1 List of key distributors and channel partners
  • Table 2 List of key emerging companies'/technology disruptors/innovators
  • Table 3 Middle East Nuclear Medicine Market, By Product, 2021 - 2033 (USD Billion)
  • Table 4 Middle East Nuclear Medicine Market, By Application, 2021 - 2033 (USD Billion)
  • Table 5 Middle East Nuclear Medicine Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 6 Saudi Arabia Nuclear Medicine Market, By Product, 2021 - 2033 (USD Billion)
  • Table 7 Saudi Arabia Nuclear Medicine Market, By Application, 2021 - 2033 (USD Billion)
  • Table 8 Saudi Arabia Nuclear Medicine Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 9 UAE Nuclear Medicine Market, By Product, 2021 - 2033 (USD Billion)
  • Table 10 UAE Nuclear Medicine Market, By Application, 2021 - 2033 (USD Billion)
  • Table 11 UAE Nuclear Medicine Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 12 Kuwait Nuclear Medicine Market, By Product, 2021 - 2033 (USD Billion)
  • Table 13 Kuwait Nuclear Medicine Market, By Application, 2021 - 2033 (USD Billion)
  • Table 14 Kuwait Nuclear Medicine Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 15 Qatar Nuclear Medicine Market, By Product, 2021 - 2033 (USD Billion)
  • Table 16 Qatar Nuclear Medicine Market, By Application, 2021 - 2033 (USD Billion)
  • Table 17 Qatar Nuclear Medicine Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 18 Oman Nuclear Medicine Market, By Product, 2021 - 2033 (USD Billion)
  • Table 19 Oman Nuclear Medicine Market, By Application, 2021 - 2033 (USD Billion)
  • Table 20 Oman Nuclear Medicine Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 21 Rest of Middle East Nuclear Medicine Market, By Product, 2021 - 2033 (USD Billion)
  • Table 22 Rest of Middle East Nuclear Medicine Market, By Application, 2021 - 2033 (USD Billion)
  • Table 23 Rest of Middle East Nuclear Medicine Market, By End Use, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Middle East Nuclear Medicine Market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Middle East Nuclear medicine market: Product outlook and key takeaways
  • Fig. 9 Middle East Nuclear medicine market: Product movement analysis & market share 2024 & 2033
  • Fig. 10 Diagnostics market, 2021 - 2033 (USD Billion)
  • Fig. 11 SPECT market, 2021 - 2033 (USD Billion)
  • Fig. 12 TC-99m market, 2021 - 2033 (USD Billion)
  • Fig. 13 TL-201 market, 2021 - 2033 (USD Billion)
  • Fig. 14 GA-67 market, 2021 - 2033 (USD Billion)
  • Fig. 15 I-123 market, 2021 - 2033 (USD Billion)
  • Fig. 16 Others market, 2021 - 2033 (USD Billion)
  • Fig. 17 PET market, 2021 - 2033 (USD Billion)
  • Fig. 18 F-18 market, 2021 - 2033 (USD Billion)
  • Fig. 19 SR-82/RB-82 market, 2021 - 2033 (USD Billion)
  • Fig. 20 PYLARIFY (piflufolastat F 18) market, 2021 - 2033 (USD Billion)
  • Fig. 21 Illuccix (gallium Ga 68 gozetotide) market, 2021 - 2033 (USD Billion)
  • Fig. 22 Others market, 2021 - 2033 (USD Billion)
  • Fig. 23 Therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 24 Alpha Emitters market, 2021 - 2033 (USD Billion)
  • Fig. 25 RA-223 market, 2021 - 2033 (USD Billion)
  • Fig. 26 Others market, 2021 - 2033 (USD Billion)
  • Fig. 27 Beta Emitters market, 2021 - 2033 (USD Billion)
  • Fig. 28 I-131 market, 2021 - 2033 (USD Billion)
  • Fig. 29 Y-90 market, 2021 - 2033 (USD Billion)
  • Fig. 30 SM-153 market, 2021 - 2033 (USD Billion)
  • Fig. 31 Re-186 market, 2021 - 2033 (USD Billion)
  • Fig. 32 Lu-177 market, 2021 - 2033 (USD Billion)
  • Fig. 33 Others market, 2021 - 2033 (USD Billion)
  • Fig. 34 Brachytherapy market, 2021 - 2033 (USD Billion)
  • Fig. 35 Cesium-131 market, 2021 - 2033 (USD Billion)
  • Fig. 36 Iodine-125 market, 2021 - 2033 (USD Billion)
  • Fig. 37 Palladium-103 market, 2021 - 2033 (USD Billion)
  • Fig. 38 Iridium-192 market, 2021 - 2033 (USD Billion)
  • Fig. 39 Others market, 2021 - 2033 (USD Billion)
  • Fig. 40 Middle East Nuclear medicine market: Application outlook and key takeaways
  • Fig. 41 Middle East Nuclear medicine market: Application movement analysis & market share 2024 & 2033
  • Fig. 42 Cardiology market, 2021 - 2033 (USD Billion)
  • Fig. 43 SPECT market, 2021 - 2033 (USD Billion)
  • Fig. 44 PET market, 2021 - 2033 (USD Billion)
  • Fig. 45 Therapeutic Applications market, 2021 - 2033 (USD Billion)
  • Fig. 46 Neurology market, 2021 - 2033 (USD Billion)
  • Fig. 47 Oncology market, 2021 - 2033 (USD Billion)
  • Fig. 48 Thyroid market, 2021 - 2033 (USD Billion)
  • Fig. 49 SPECT market, 2021 - 2033 (USD Billion)
  • Fig. 50 Therapeutic Applications market, 2021 - 2033 (USD Billion)
  • Fig. 51 Lymphoma market, 2021 - 2033 (USD Billion)
  • Fig. 52 Bone Metastasis market, 2021 - 2033 (USD Billion)
  • Fig. 53 SPECT market, 2021 - 2033 (USD Billion)
  • Fig. 54 Therapeutic Applications market, 2021 - 2033 (USD Billion)
  • Fig. 55 Endocrine Tumor market, 2021 - 2033 (USD Billion)
  • Fig. 56 Pulmonary Scans market, 2021 - 2033 (USD Billion)
  • Fig. 57 Urology market, 2021 - 2033 (USD Billion)
  • Fig. 58 Other market, 2021 - 2033 (USD Billion)
  • Fig. 59 Middle East Nuclear medicine market: End Use outlook and key takeaways
  • Fig. 60 Middle East Nuclear medicine market: End Use movement analysis & market share 2024 & 2033
  • Fig. 61 Hospitals market, 2021 - 2033 (USD Billion)
  • Fig. 62 Diagnostic Centers market, 2021 - 2033 (USD Billion)
  • Fig. 63 Others market: Disease outlook and key takeaways
  • Fig. 64 Middle East market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 65 Saudi Arabia market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 66 UAE market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 67 Kuwait market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 68 Qatar market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 69 Oman market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
  • Fig. 70 Rest of Middle East market size, & forecasts and trend analysis, 2021 to 2033 (USD Billion)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!